Shots:

• The CALAVI study is a two-part trial assessing the efficacy and safety of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19
• Part 1 randomized patients in a ratio (2:1) and evaluates Calquence + BSC in patients who are hospitalized- but not on assisted ventilation & not in the ICU while part two evaluates therapy in a cohort of patients in the ICU with more severe respiratory complications
• The goal of the study to reduce mortality and the need for assisted ventilation in patients with life-threatening COVID-19 symptoms. Calquence is a BTK inhibitor act by binding covalently to BTK further inhibiting its activity in the beta-cell

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image: Student Show